Ibuprofen/famotidine
| Combination of | |
|---|---|
H2 antagonist | |
| Clinical data | |
| Trade names | Duexis |
| Other names | HZT-501 |
| AHFS/Drugs.com | Micromedex Detailed Consumer Information |
| License data | |
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| KEGG | |
Ibuprofen/famotidine, sold under the brand name Duexis, is a
H2-receptor antagonist.[1]
Ibuprofen/famotidine is available as a
generic medication.[2]
References
- ^ a b c "Duexis- ibuprofen and famotidine tablet, coated". DailyMed. Retrieved 6 August 2021.
- ^ "Generic Duexis Availability". Drugs.com. 9 March 2023. Retrieved 17 March 2023.
Further reading
- Bello AE (October 2012). "Duexis (ibuprofen 800 mg, famotidine 26.6 mg): a new approach to gastroprotection for patients with chronic pain and inflammation who require treatment with a nonsteroidal anti-inflammatory drug". Therapeutic Advances in Musculoskeletal Disease. 4 (5): 327–39. PMID 23024710.
- Deeks ED (September 2013). "Fixed-dose ibuprofen/famotidine: a review of its use to reduce the risk of gastric and duodenal ulcers in patients requiring NSAID therapy". Clin Drug Investig. 33 (9): 689–97. S2CID 24972423.
External links
- "Famotidine mixture with ibuprofen". Drug Information Portal. U.S. National Library of Medicine.
| pyrazolones / pyrazolidines | |
|---|---|
| salicylates | |
| acetic acid derivatives and related substances | |
| oxicams | |
profens ) |
|
| n-arylanthranilic acids ( fenamates ) | |
COX-2 inhibitors (coxibs) | |
| other | |
| NSAID combinations | |
Key: underline indicates initially developed first-in-class compound of specific group; #WHO-Essential Medicines; †withdrawn drugs; ‡veterinary use. | |
